Kirkland Represents Samumed on Exclusive License Agreement with United Therapeutics for Samumed's IPF Drug Candidate

Kirkland & Ellis LLP advised Samumed LLC, a leader in medical research and development for tissue-level regeneration, on its exclusive license agreement with United Therapeutics Corporation (Nasdaq :UTHR ), a biotechnology company, for the North American rights to Samumed's SM04646 which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). Deal terms include $10 million up-front with up to $340 million in developmental milestones plus certain royalties. The full press release is available here.

The Kirkland team was led by technology & IP transactions partners Adam Petravicius, Seth Traxler and David MacDonald and associate Matt Darch, with support from corporate partner Christian Atwood, antitrust partner Matt Reilly, and tax partner Vincent Thorn.